key: cord-0321812-wzdgizoo
authors: Bouwman, Wilbert; Verhaegh, Wim; Holtzer, Laurent; van de Stolpe, Anja
title: Quantitative measurement of activity of JAK-STAT signaling pathways in blood samples and immune cells to predict innate and adaptive cellular immune response to viral infection and accelerate vaccine development
date: 2020-05-15
journal: bioRxiv
DOI: 10.1101/2020.05.13.092759
sha: 20f73c6c25ddb11e7cf6f26981a7d9bb829503f6
doc_id: 321812
cord_uid: wzdgizoo

The host immune response determines the clinical course of a viral infection, for example in case of COVID-19 infection. The effectiveness of vaccination also depends on the induced immune response. Currently there is no method to measure the cellular immune response in blood samples. The functional activity of cells of innate and adaptive immune system is determined by coordinated activity of signaling pathways, especially the JAK-STAT pathways. Using a previously described approach we developed mRNA-based tests to measure activity of these signaling pathways, and show that they can be used to measure in a quantitative manner the cellular innate and adaptive immune response to a viral infection or vaccine in whole blood, PBMC, and specific immune cell type samples. Pathway activity level and range in healthy individuals was established, enabling interpretation of a pathway activity score on a patient sample without the need for a reference sample. Evidence is presented that the pathway activity analysis may also be useful for in vitro vaccine development and assessment of vaccine immunogenicity. Other envisioned applications lie in development of immunomodulatory drugs and drug response prediction and monitoring. Tests are expected to be of value in the COVID-19 crisis. In addition to the described Affymetrix microarray-based pathway tests for measuring host immune response, qPCR-based versions are in development; the latter can in principle be performed within three hours in routine hospital labs.

A good functioning immune system is crucial to protect against diseases, such as viral and bacterial infections and cancer (1). It generates an immune response to non-self antigens, such as a component of a virus, or an abnormal protein produced by a cancer cell. Briefly and highly simplified, an immune response consists of an innate immune response which has an inflammatory component and is responsible for rapid non-specific attack and removal of pathogens and for presentation of pathogen-derived antigens to the cells of the adaptive immune response, which is responsible for generating long term immunity. Both parts of the immune system contain different immune cell types that cooperate to generate an effective immune response. They communicate via a large number of cytokines, such as interleukins and interferons. Cytokines convey messages from one cell to the other by binding to specific cellular receptors to activate cellular signal transduction pathways, especially the JAK-STAT pathways, resulting in production of proteins that adapt the function of the immune cell as response to the cytokine signal. In this highly organized system, dendritic cells are the most important antigen presenting cells bridging the innate and adaptive immune system. The adaptive immune response consists of a humoral response, that is, antibodies specifically generated against the pathogen by B-cells, and a cellular immune response, effectuated by cytotoxic T-cells. For an adequate response to a dominantly intracellular pathogen, such as a virus or in case of cancer cells, the cellular immune response is of prime importance, in addition to the production of neutralizing antibodies. The effectiveness with which the immune system can mount a response Page3 to a pathogen is determined by multiple factors, such as the amount and type of pathogen, genetic variations in relevant immune genes, patient comorbidities, and use of drugs which may have a suppressive, or stimulating, effect on the immune system. Viral infections can create worldwide disasters, as exemplified by the COVID-19 pandemic, caused by the SARS-CoV-2 virus (2). A major clinical problem caused by infection with this respiratory virus is rapid deterioration in a subset of patients with pneumonia, requiring admission to an intensive care unit (ICU), frequently with prolonged invasive ventilation and detrimental outcome (3), (4) . Other respiratory viruses, such as other coronaviruses (e.g. SARS and MERS) but also other viruses like the Respiratory Syncytial Virus (RSV) can cause similar clinical behavior in a subset of patients. Many other types of viruses, that do or do not specifically target the respiratory system, can also cause epidemics associated with high mortality and serious complications, e.g. influenza, ebola, measles, yellow fever, etc.

The clinical course of a viral infection is strongly determined by the host immune response, emphasized in the case of COVID-19 by the extreme differences in symptomatology and clinical outcome, ranging from mild symptoms, or even unnoticed infection, to Acute Respiratory Distress Syndrome (ARDS) with high mortality rate (2),(3), (5) . Measuring the functional state of the innate and adaptive immune response in a blood sample of a patient is expected to improve prognosis prediction, and to support development of vaccines and safe immunomodulatory treatments to improve immune response and clinical outcome.

We describe development, as well as evaluation in preclinical and clinical studies, of an mRNAbased test to quantify the immune response to a viral infection, based on measuring activity of the JAK-STAT1/2 and JAK-STAT3 signal transduction pathways in a whole blood or Peripheral Blood Mononuclear Cell (PBMC) sample, or in separate immune cell types. The technology used to develop tests to measure activity of signal transduction pathways is based on measuring the mRNA levels of target genes of the pathway-specific transcription factor and has been described before (6),(7),(8),(9),(10), (11) , (12) , (13) .

Development of tests to measure JAK-STAT1/2 and JAK-STAT3 pathway activity were developed as described before (6),(7), (8) . In brief, target genes of the STAT transcription factors of the respective pathways were identified, and a Bayesian network computational model was created Page4 for interpretation of measured mRNA levels of the pathway target genes. For the purpose of this study, target gene mRNA levels were derived from Affymetrix expression microarray data (6) .

The mathematical approach to develop Bayesian network models for the interpretation of the transcription factor target gene mRNA levels has been described previously in detail (6) . A causal computational network model is built, enabling inference of the probability that the pathwayassociated transcription factor is in an active state, binding to and transcribing its target genes ( Figure S1 ). The Bayesian network describes (i) the causal relation that a target gene is up-or downregulated depending on the transcription factor being active or inactive and (ii) the causal relation that an AffymetrixU133Plus2.0 probeset signal is high or low, depending on the target gene being up-or down regulated. Model parameters for (i) have been based on literature evidence, and for (ii) are based on data from calibration samples with known signalling pathway activity, that is, either active or inactive. Target genes for the JAK-STAT1/2 and JAK-STAT3 pathway model were selected using available scientific literature (Supplementary Table S2, and Supplementary methods). Following model calibration and model parameter freeze, mRNA probeset measurements of a new sample can be entered into the model, and Bayesian inference is used to calculate probability P that the transcription factor, and therefore the signalling pathway, is active. Pathway activity score can be presented as log2odds value log2 (P / (1 -P)), which can optionally be normalized on a scale from 0-100 (6),(7), (8) . Quantitative log2odds pathway activity scores are used in the figures and results description. JAK-STAT1/2 and JAK-STAT3 Pathway models were biologically validated on independent public available (14) Affymetrix HG-U133Plus2.0 microarray data of samples with known pathway activity.

Using the developed signaling pathway tests for JAK-STAT1/2 and JAK-STAT3 pathways, public Affymetrix HG-U133Plus2.0 microarray expression datasets from preclinical and clinical studies (deposited in the GEO database (14)) were analyzed and log2odds pathway activity scores calculated. In one dataset a previously described pathway test to measure NFκB pathway activity was used (8) .

Quality control (QC) was performed on Affymetrix data of each individual sample (15) , (16) . In summary, QC parameters include: the average value of all probe intensities, presence of negative or extremely high (> 16-bit) intensity values, poly-A RNA (sample preparation spike-ins) and labelled cRNA (hybridization spike ins) controls, GAPDH and ACTB 3'/5' ratio, centre of intensity and values of positive and negative border controls determined by affyQCReport package in R, and an RNA degradation value determined by the AffyRNAdeg function from the Affymetrix package in R (17) , (18) . Samples that failed QC were removed prior to data analysis.

Boxplots and individual sample plots were made using the Python data visualization library function seaborn; additional statistical annotations were created using the Python package statannot (19),(20). T-test or two sided Mann-Whitney-Wilcoxon testing was used to compare pathway activity scores across groups. p-values are indicated in the figures.

Target genes that were identified and used to develop the JAK-STAT1/2 models and the JAK-STAT3 models are listed in Supplementary Table S1. The Bayesian model developed for the JAK-STAT1/2 pathway was calibrated on Affymetrix data from samples stimulated with IFN type II (GSE38351, (21) ). Both types of interferon activate the JAK-STAT1/2 pathway (22) . In this study, PBMC samples from patients with rheumatoid arthritis had been stimulated with type I and type II IFN, while untreated samples and TNFα-stimulated samples were used as STAT1/2 pathway inactive controls ( Figure S2A ). The calibrated JAK-STAT1/2 pathway model measured both IFN type I and type II activity of the JAK-STAT1/2 pathway ( Figure S2B ). Biological validation of the calibrated and frozen pathway model was performed on independent datasets in which either IFN type I or IFN type II had activated the pathway. Pathway activity was correctly measured in natural killer (NK) cells stimulated in vitro with IFNα-2b (IFN type I) ( Figure S2C The JAK-STAT3 pathway can be activated by several cytokines that bind to their respective receptors, resulting in activation of JAK1 and formation of a STAT3 homodimer which transcribes target genes (28) , (29) . The JAK-STAT3 pathway model was calibrated on T cell leukemia cells, in the absence or presence of interleukin 2 (IL2) stimulation to activate the pathway ( Figure S3A ) (GSE8687, (30) ). Validation of the JAK-STAT3 pathway model was performed on independent datasets with known JAK-STAT3 pathway activity: IL-2, IL-15, and IL10, known to induce JAK-STAT3 pathway activity, induced an increase in pathway activity scores in a Sezary (Sez) cutaneous lymphoma cell line and in PBMCs (Figures S3B, S3C) (GSE8685, (30) ; GSE43700, (31)).

IgG was also reported to induce JAK-STAT pathway activity and incubation of the Sez cell line with IgG-coated beads increased JAK-STAT3 pathway activity scores ( Figure S3D ) (GSE8507, (32) ). In clinical patient sample data of knee synovial biopsies from patients with rheumatoid arthritis JAK-STAT3 pathway activity scores decreased after treatment with Tocilizumab, an inhibitor of the IL6 ligand of the JAK-STAT3 pathway, and not after treatment with methotrexate ( Figure S3E ) (GSE45867, (33) ). In summary, the JAK-STAT1/2 and the JAK-STAT3 pathway model performed as expected on independent preclinical and clinical sample data. 

Some viral infections are known for their variation in disease severity. The RSV virus is a respiratory RNA virus which predominantly infects children and presents with a large variation in disease severity. Dengue virus infection also can run a more severe disease course, presenting as Dengue Hemorrhagic Fever (DHF). In PBMC samples of patients with one of these viral infections, JAK-STAT1/2 pathway activity scores were increased irrespective of the degree of severity of the infection (Figure 2A and 3A) . However, activity of the JAK-STAT3 pathway was significantly higher in RSV patients who presented with a severe disease course, and also higher in patients with JAK-STAT1/2 pathway JAK-STAT3 pathway Page8 DHF, however the latter did not reach significance (n=3) ( Figure 2B and 3B) . In a separate clinical study, CD8+ T cells had been isolated from patients with Dengue and Dengue Hemorrhagic Fever (DHF). In this T cell subtype, again activity of both JAK-STAT pathways was increased in patients, but JAK-STAT3 pathway activity was not higher in the severe DHF disease variant ( Figure 3C ,D).

Dengue virus can induce partial immunosuppression, and the PBMC blood samples that had been collected at various time points during the disease enabled investigation of the relation between JAK-STAT pathway activity and this immunosuppressive effect of the virus. JAK-STAT1/2 pathway activity rapidly decreased; in DHF the decrease was already significant two days after clinical presentation, in DF after day 5, while the JAK-STAT3 pathway activity decreased more slowly during the disease ( Figure 3A,B) . Influenza virus is known to generally induce a stronger immunity than RSV. In the analyzed study, this was associated with higher JAK-STAT1/2 pathway activity, but not JAK-STAT3 pathway activity, in PBMCs of patients with influenza infection, compared to RSV infected patients ( Figure   4 ). 

Three clinical vaccination studies with yellow fever and influenza virus were analyzed. For yellow fever vaccination, healthy individuals were immunized with a live attenuated strain of the yellow fever virus (YFV-17D). In PBMCs ( Figure 6A ), as well as in CD4+ T cells and two monocyte subsets ( Figure 6C , isolated before and after vaccination with the live Yellow Fever vaccine, JAK-STAT1/2 pathway activity scores increased after vaccination, compatible with induction of immunity ( Figure 6A,C) . JAK-STAT3 pathway activity scores were only increased in monocytes ( Figure 6D ).

In contrast to Yellow Fever vaccination, vaccination with Trivalent inactivated nfluenza Vaccine Table S3 ).

Combining these groups, the mean JAK-STAT1/2 pathway activity score was -5.95 log2odds (SD Table S3 ). Based on this, we propose to define an initial upper threshold for JAK-STAT1/2 pathway activity score in healthy individuals as the mean value + 2SD, resulting in a threshold of -0.41 log2odds for the pathway activity score, when measured on a PBMC sample.

The upper threshold for JAK-STAT3 pathway activity score, calculated in the same way, was -4.42 log2odds, when measured in a PBMC sample.

We describe development of mRNA-based tests to quantify activity of the JAK-STAT1/2 and JAK-STAT3 signal transduction pathways in immune cells, and based on analysis of multiple clinical studies (influenza, RSV, yellow fever, dengue, rotavirus infections) provide evidence for value of the tests to quantify the host cellular immune response to a viral infection or vaccine.

Measured JAK-STAT1/2 pathway activity scores in patient blood samples provided information on the adaptive immunity generated by viral infections, where a higher pathway activity was associated with development of a stronger adaptive immune response. This JAK-STAT pathway is known to perform key functions in generating an antiviral immune response (22) , (44) , (45) .

In most of the analyzed studies, PBMC samples had been collected that consist predominantly of lymphocytes and monocytes. Analysis of a Dengue infection and a Yellow Fever vaccination study, in which data were available from isolated T cells and monocytes, suggested that both lymphocytes and monocytes contributed to the increase in pathway activity seen in PBMCs -in line with the role of the JAK-STAT1/2 pathway in the immune response against viral infection.

The increase in JAK-STAT1/2 pathway activity in PBMCs was only observed in viral infections, and not in bacterial infections. Interferons are well known to be specifically induced by a viral infection and to activate the JAK-STAT1/2 pathway to elicit an antiviral immune response (22) , (44) , (45) . In line with this, the pathway test may have potential value in distinguishing between viral and bacterial infections.

Some viruses can induce a stronger and longer lasting adaptive immunity than others, and measured JAK-STAT1/2 pathway activity scores nicely reflected such differences. Influenza virus infection appeared to be associated with a higher JAK-STAT1/2 pathway activity in PBMCs than infection with RSV. Indeed, in general in the population the immune response generated by the RSV virus is lower and less persistent than immunity induced by the influenza virus (37) . In Dengue infection, JAK-STAT1/2 pathway activity in PBMCs already started to decline within a few days after clinical presentation. This may have reflected the immunosuppressive effect of the Dengue virus, which has been reported to impair interferon-mediation induction of STAT1/2 activity (36) , (46) , (47) . Finally, in the one study in which dendritic cells of patients with chronic persistent HBV infection were analyzed, JAK-STAT1/2 pathway activity was not increased at all. This was in line with described reduced functionality of DCs in chronic HBV infection, resulting in lack of adaptive immunity and chronic persistence of the HBV virus (38) .

The immune response to infection with the same virus type is known to vary among patients (48) . Overall we observed a large variation in JAK-STAT1/2 pathway activity between individual patients with a specific acute viral infection. While we cannot exclude that this may in part have been due to blood sampling at different time points during the disease, a more likely explanation is that it reflects differences in the individual patient capability to mount an adaptive immune response and generate immunity against the virus. Many factors influence this capability, like genetic variations, age, comorbidities like diabetes, and immune modifying drugs like corticosteroids (48) , (49) , (50) .

Taken together, results suggest that measuring JAK-STAT1/2 pathway activity in PBMCs, or T cell subsets, and even in whole blood samples, during active viral infection may provide relevant information on the strength of the host immune response to induce adaptive immunity against the virus.

Changes in activity of the JAK-STAT3 pathway during viral infection frequently paralleled JAK-STAT1/2 pathway activity when measured on the same PBMC samples. However in contrast to the JAK-STAT1/2 pathway, JAK-STAT3 pathway activity increased more in monocytes than in Tcells. This suggests that activity of this signaling pathway is more associated with activity of the innate immune response, represented by the monocyte fraction in PBMC samples. Indeed, the JAK-STAT3 pathway is also involved in viral disease, and in addition to a role in generating a host immune response, its activity has been associated with severe inflammatory complications caused by a disbalance between adaptive and innate immune response, such as COVID-19 pneumonia (51), (52) , (53) , (54) .

In two studies in which samples had been obtained from RSV and Dengue patients characterized by differences in disease severity, JAK-STAT3 pathway activity scores were higher in patients with a more severe disease course, although for Dengue only three such patient samples could be analyzed. Such high JAK-STAT3 pathway activity may have been induced by circulating cytokines such as IL6, IL10 or TNFα. These cytokines have been reported to be elevated in respiratory viral infections associated with severe infection of the lower airways and pneumonia, such as caused by RSV and more recently also SARS-CoV-2 (COVID-19), reflecting dominant activity of the innate immune response (55) , (56) , (57) .

We believe that measuring JAK-STAT3 pathway activity in addition to JAK-STAT1/2 pathway activity may provide complementary information, that is, on the extent to which the innate immune response is activated, and potentially on the balance between adaptive and innate (inflammatory) response.

Absolute measured JAK-STAT pathway activity scores in healthy individuals were very comparable between different studies when obtained on the same type of blood sample. This allowed the calculation of an initial threshold value for PBMC samples above which a JAK-STAT1/2 or JAK-STAT3 pathway activity score may be considered as higher than normal, as found in healthy individuals. In view of the limited number of analyzed samples, these initial threshold levels need further confirmation. However, the high reproducibility between the different clinical studies suggests that defining a normal ("healthy") range of JAK-STAT pathway activity in blood samples will be feasible. This will be of clinical relevance when assessing the immune response in virally infected patients, from whom usually no healthy reference blood sample will be available.

Analysis of clinical vaccination studies provided support for the potential of using the JAK-STAT1/2 pathway activity score to predict vaccine immunogenicity and the induction of a cellular adaptive immune response. Yellow Fever (YF) vaccination induced a large increase in JAK-STAT1/2 pathway activity in PBMCs, both in T cells and monocytes, in all vaccinated individuals, within 3 days after vaccination. YF vaccine consists of an attenuated live virus, which infects dendritic cells, resulting in highly effective T cell activation, and excellent immunity (39) . In contrast, after vaccination with a Trivalent Influenza Vaccine (TIV), no such increase in pathway activity was found, while during actual influenza virus infection JAK-STAT1/2 pathway activity did increase. This suggests that the vaccine had not induced adaptive cellular immunity, despite a satisfactory humoral antibody response in 22 out of 28 individuals (40) . In contrast to the live virus YF vaccine, TIV contains inactivated virus. The inactivated virus vaccine may have lost the capability of the wild type virus to induce complete maturation and activation of dendritic cells, necessary to optimally activate T cells. Influenza vaccination not always induces satisfactory immunity and addition of an adjuvant compound to TIV was reported to increase immunogenicity (58) , (59) , (60) . More recently, for this reason adjuvant-containing influenza vaccines have been introduced to increase influenza immunity in the aging population (61) .

In addition to use for quantifying clinical effectiveness of a vaccine, the JAK-STAT1/2 pathway test may also be of value for in vitro vaccine development, as shown by our analysis of the study in which the immunogenicity of HIV had been investigated (62) . HIV is not immunogenic by itself because the virus cannot infect DCs, however when infection was enabled in vitro, the DC activation process necessary to generate an immune response appeared to be fully functional Page22 (62) . Only in the latter case, JAK-STAT1/2 pathway activity scores increased in DCs, together with increased activity of the NFκB pathway, together representing the main signaling pathways that need to be activated for effective DC antigen presentation (42) .

The value of pathway activity measurement in immune cells is expected to be complementary to conventional IgG/IgM antibody testing (59) . Because of the quantitative nature of the pathway tests, we expect that cellular effects of multiple vaccines can be rapidly quantitatively compared in vitro and a T cell immune response measured within 3-7 days after vaccination.

To the best of our knowledge, sofar it has not been possible to measure the cellular adaptive For clinical use in patients with a viral infection, it will be important to have the pathway activity test results in time to take clinical decisions. In the current study JAK-STAT pathway analysis was performed on Affymetrix expression microarray data. While of value for certain clinical studies, Affymetrix-based tests are not compatible with routine clinical use. For this reason, development of qPCR-based JAK-STAT pathway tests is in progress to reduce assay time (in principle within three hours) for routine clinical use, in a similar manner as described before for the ER signaling pathway test (11) ,(67).

Rapid assessment of the cellular host immune response in a COVID-19 patient is needed to (a) improve prediction of prognosis and identification of patients at high risk for progression to COVID-19 pneumonia and ARDS, and prediction of clinical benefit of invasive ventilation at the ICU; (b) choose the optimal treatment, including immunomodulatory drugs; (c) assess effect of exploratory treatments on adaptive and innate (inflammatory) immune response; (d) develop better models to predict evolution of the pandemic; (e) accelerate vaccine development and clinical vaccine testing; (f) development of novel drugs to strengthen the adaptive immune response, while inhibiting the late inflammatory response associated with severe pneumonia and ARDS. We hope that the tests to quantitatively measure JAK-STAT1/2 and JAK-STAT3 signaling pathway activity in immune cells and blood samples can contribute to solutions for the COVID-19 crisis. Studies on measuring host immune response on blood samples from patients with COVID-19 infection are being initiated.

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease

The trinity of COVID-19: immunity, inflammation and intervention

Selection of personalized patient therapy through the use of knowledge-based computational models that identify tumor-driving signal transduction pathways

Assessment of Functional Phosphatidylinositol 3-Kinase Pathway Activity in Cancer Tissue Using Forkhead Box-O Target Gene Expression in a Knowledge-Based Computational Model

Enabling precision medicine by unravelling disease pathophysiology: quantifying signal transduction pathway activity across cell and tissue types. Sci Rep

Knowledge-based computational models

Quantitative Measurement of Functional Activity of the PI3K Signaling Pathway in Cancer

Estrogen Receptor Pathway Activity Score to Predict Clinical Response or Resistance to Neoadjuvant Endocrine Therapy in Primary Breast Cancer

Prediction of clinical benefit from androgen deprivation therapy in salivary duct carcinoma patients

ER and PI3K Pathway Activity in Primary ER Positive Breast Cancer Is Associated with Progression-Free Survival of Metastatic Patients under First-Line Tamoxifen. Cancers (Basel)

Simpleaffy: a BioConductor package for Affymetrix Quality Control and data analysis

Quality assessment of Affymetrix GeneChip data

AffyQCReport: QC report generation for affyBatch objects

affy--analysis of Affymetrix GeneChip data at the probe level

Cellspecific type I IFN signatures in autoimmunity and viral infection: what makes the difference?

Mechanisms of type-I-and type-II-interferon-mediated signalling

Interferonalpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection

Combinatorial cytokine code generates anti-viral state in dendritic cells

SP110b Controls Host Immunity and Susceptibility to Tuberculosis

The MAPK-Activated Kinase MK2 Attenuates Dendritic Cell-Mediated Th1 Differentiation and Autoimmune Encephalomyelitis

Integrated regulation of Toll-like receptor responses by Notch and interferon-gamma pathways

Mechanisms and consequences of Jak-STAT signaling in the immune system

Revisiting STAT3 signalling in cancer: new and unexpected biological functions

Differential effects of interleukin-2 and interleukin-15 versus interleukin-21 on CD4+ cutaneous T-cell lymphoma cells

Type I interferon suppresses type II interferon-triggered human anti-mycobacterial responses

STAT3 mutations in the hyper-IgE syndrome

Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium

Olfactomedin 4 Serves as a Marker for Disease Severity in Pediatric Respiratory Syncytial Virus (RSV) Infection

Sequential waves of gene expression in patients with clinically defined dengue illnesses reveal subtle disease phases and predict disease severity

Characterization of Human CD8 T Cell Responses in Dengue Virus-Infected Patients from India

Plasticity and virus specificity of the airway epithelial cell immune response during respiratory virus infection

Characteristics of Impaired Dendritic Cell Function in Patients With Hepatitis B Virus Infection

Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans

Systems biology of vaccination for seasonal influenza in humans

Toll-Like Receptor Signaling Pathways. Front Immunol

STING: infection, inflammation and cancer

Gene expression analysis in children with complex seizures due to influenza A(H1N1)pdm09 or rotavirus gastroenteritis

Decoding type I and III interferon signalling during viral infection

Direct Antiviral Mechanisms of Interferon-Gamma. Immune Netw

Innate immunity evasion by Dengue virus

Innate immunity to dengue virus infection and subversion of antiviral responses

Human immune system variation

Factors That Influence the Immune Response to Vaccination

Innate and adaptive immune traits are differentially affected by genetic and environmental factors

Viral manipulation of STAT3: Evade, exploit, and injure

Pro-Inflammatory Signaling by IL-10 and IL-22: Bad Habit Stirred Up by Interferons? Front Immunol

STAT3 roles in viral infection: antiviral or proviral? Future Virology

The Role of Interleukin 6 During Viral Infections. Front Microbiol

COVID-19: consider cytokine storm syndromes and immunosuppression. The Lancet

The pathogenesis and treatment of the `Cytokine Storm' in COVID-19

CoV-2: a storm is raging

Adjuvanted influenza vaccines

Next-generation influenza vaccines: opportunities and challenges

Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine. Vaccine

FLUAD TM Flu Vaccine With Adjuvant| Seasonal Influenza (Flu) | CDC

A cryptic sensor for HIV-1 activates antiviral innate immunity in dendritic cells

The Interplay of Notch Signaling and STAT3 in TLR-Activated Human Primary Monocytes. Front Cell Infect Microbiol

Gene regulation and signal transduction in the immune system

Regulation of the Immune Response by TGF-β: From Conception to Autoimmunity and Infection

Comprehending a Killer: The Akt/mTOR Signaling Pathways Are Temporally High-Jacked by the Highly Pathogenic 1918 Influenza Virus

We acknowledge Meng Dou and Henk van Ooijen for their valuable contributions to development of the JAK-STAT1/2 and JAK-STAT3 pathway models; and Diederick Keizer, Martijn Akse, and Sigi Neerken, for thoroughly reviewing the manuscript and providing valuable suggestions for improvement. We also wish to acknowledge all investigators who generated the used invaluable GEO datasets.